We know that our ground-breaking treatments have the potential to treat a range of malignancies and make a drastic difference to lives of millions of cancer patients, globally.

There are unique synergies when CAR T therapeutic technology is applied to the novel oncology target nfP2X7 that has been characterised and developed by Biosceptre.

Our pioneering BRiDGECAR™ system combines highly potent CAR-T therapy with multiple targeted antibodies and is designed to be the next generation of cancer therapy, with the potential of delivering unprecedented outcomes to many types of cancer.


Available for Out-licensing

  • BIL06v Peptide Vaccine
  • BIL010t Polyclonal Antibody Topical Therapeutic (BCC)